Listen to this story
Subscriber Benefit
As a subscriber you can listen to articles at work, in the car, or while you work out. Subscribe Now0:00
0:00
Loading audio file, please wait.
Eli Lilly and Co.’s osteoporosis drug Evista has been approved to reduce risk of invasive breast cancer in postmenopausal women with osteoporosis and postmenopausal women at high risk for invasive breast cancer, the Indianapolis drugmaker announced today.
The U.S. Food and Drug Administration move came after an FDA advisory panel in late July recommended the approval.
Lilly is looking for more uses for the drug, which generates $1 billion a year in sales, because it expects sales to weaken in the next several years. A patent on the drug expires in 2014.
Please enable JavaScript to view this content.